The First Longevity Board: How Insilico Medicine Is Using AI to Target the Biology of Aging Itself

For the first time, a pharmaceutical AI company has convened a dedicated governing body charged with one mission: translating the science of biological aging into drugs that extend healthy human lifespan. Here is what it means.

Presented By Our Partners

Something shifted in the world of aging research on April 21, 2026. Insilico Medicine, the generative AI drug discovery company whose platform became the first AI system to take a novel drug from target identification to Phase 2 clinical data, announced the formation of the industry’s first Longevity Board. It is not a marketing exercise. The Board is chaired by Andrew Adams, Group Vice President of Molecular Discovery at Eli Lilly and Company, and counts Nobel laureate Michael Levitt among its founding members. Its mandate is to provide scientific oversight and strategic direction for a specific, ambitious goal: finding drugs that do not just treat the symptoms of aging-related disease but act on the fundamental biology of aging itself.

That distinction, between treating diseases that aging causes versus intervening in the biological process of aging, represents one of the most consequential fault lines in 21st-century medicine. Insilico is now formally betting its institutional weight on the right side of it.

What the Longevity Board Actually Does

The Longevity Board is not a scientific advisory panel in the traditional sense. Its role goes beyond reviewing papers and offering opinions. According to the announcement, the Board will oversee four specific workstreams: life models and aging biology, biomarkers of aging, the identification of dual-purpose targets positioned at the intersection of chronic disease and aging biology, and clinical development programs that validate therapeutic effects on the hallmarks of aging using both established biomarkers and emerging foundation models.

That fourth workstream is where the most significant clinical stakes lie. Validating that a drug actually modulates the hallmarks of aging, rather than just treating a single disease, requires a new class of trial design and a new class of biomarkers. The Board is being asked to make those design decisions with real drugs and real patients.

Alex Zhavoronkov, Co-CEO of Insilico Medicine, framed the intent precisely: “We are not just building a pipeline. We are building the infrastructure to prove that aging is a tractable drug target, and to do it with the kind of scientific credibility that moves the whole field.” Feng Ren, co-CEO alongside Zhavoronkov, has spent years building the platform that is now being pointed at this larger question.

The Proven AI Platform Behind the Ambition

Before assessing what the Longevity Board might accomplish, it is worth understanding what Insilico has already built. The company operates a fully integrated AI drug discovery platform built around two core systems: PandaOmics, a target identification engine trained on multi-omics and clinical datasets, and Chemistry42, a generative chemistry system that designs novel small molecules against those targets. Together, they compressed the traditional early drug discovery timeline from years to months.

The flagship demonstration of this capability was rentosertib, also known as ISM001-055, a first-in-class small-molecule inhibitor of TNIK (Traf2- and NCK-interacting kinase) developed for idiopathic pulmonary fibrosis. Insilico took rentosertib from an identified target to Phase 1 clinical entry in just 30 months, a timeline that would have been considered impossible under conventional drug discovery methods. A randomized Phase 2a trial, published in Nature Medicine in early 2025, reported encouraging clinical efficacy, including improvement in forced vital capacity at 12 weeks alongside a favorable safety and tolerability profile.

That Phase 2a readout was not just a clinical milestone. It was a proof of concept for the underlying argument: that generative AI can discover novel mechanisms, design drugs against them, and generate clinical signal in human patients. The Longevity Board is now being tasked with scaling that logic to the most complex target of all, namely, aging itself.

Targeting the Hallmarks of Aging, Not Just the Diseases

The scientific framework guiding this work comes from the field of geroscience, specifically the concept of the hallmarks of aging first formally described in a landmark 2013 paper by Lopez-Otin and colleagues in Cell, and substantially updated in a 2023 revision that expanded the list to twelve hallmarks. These include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation (now called “inflammaging”), and dysbiosis.

The hallmarks framework transformed aging research by providing a mechanistic vocabulary. Instead of asking “why do people age?”, researchers could now ask which specific molecular and cellular processes go wrong, in which tissues, at which rates, and with which downstream consequences. More importantly for drug development, the framework identified specific nodes that are, in principle, druggable.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Insilico’s PandaOmics platform has been trained on datasets related to these hallmarks, allowing it to identify candidate targets that appear at the intersection of aging biology and specific disease phenotypes. The TNIK target behind rentosertib is itself connected to aging biology, as fibrosis is a hallmark-driven pathology involving senescent cell activity, extracellular matrix dysregulation, and inflammaging. Early preclinical work suggested that ISM001-055 functions as a senomorphic agent, suppressing the secretory activity of senescent cells rather than eliminating them, a therapeutic modality now receiving significant attention in the senescence field.

A 2025 study in GeroScience examining senomorphic versus senolytic strategies noted that agents capable of modulating the senescence-associated secretory phenotype without killing cells may offer a more practical route to clinical translation, given the potential toxicity concerns that surround broad senolytic approaches. Insilico’s work with TNIK inhibition sits squarely in this emerging therapeutic space.

The Dual-Purpose Target Strategy

One of the most intellectually compelling aspects of the Longevity Board’s mandate is the emphasis on what Insilico calls “dual-purpose targets.” The concept is straightforward in principle but technically demanding in execution: identify molecular targets that are implicated both in the progression of a specific, diagnosable disease and in the fundamental processes of biological aging. A drug developed against such a target could, in theory, provide both a near-term clinical benefit that satisfies regulatory requirements and a longer-term effect on aging biology that would be validated through biomarkers over time.

This strategy sidesteps one of the central regulatory challenges in longevity medicine. The U.S. Food and Drug Administration does not currently recognize “aging” as an indication that can anchor a drug approval, although the ongoing TAME trial (Targeting Aging with Metformin) has been designed in part to establish whether that regulatory pathway might eventually be opened. Until it is, drugs that target aging biology must earn their approval by treating a recognized disease. Dual-purpose targets allow companies to pursue both objectives simultaneously.

Andrew Adams, who chairs the Longevity Board, has spent his career at the intersection of structural biology, computational chemistry, and large-scale pharmaceutical development at Lilly. His involvement signals something important: one of the world’s largest pharmaceutical companies is putting senior scientific leadership into an AI-driven longevity program at a time when most of the industry still treats aging biology as a speculative bet. The strategic positioning here is deliberate. Lilly has already demonstrated, through its work with donanemab in Alzheimer’s disease and its GLP-1 franchise, that it can move quickly from mechanistic insight to clinical scale when the science is right.

Michael Levitt and the Computational Case for Longevity

The presence of Michael Levitt on the Longevity Board carries its own significance. Levitt won the 2013 Nobel Prize in Chemistry alongside Martin Karplus and Arieh Warshel for the development of multiscale models for complex chemical systems, work that laid the computational foundation for modern molecular dynamics simulations and, by extension, structure-based drug design. He has been a member of Insilico’s Scientific Advisory Board since 2014, making him a long-standing intellectual collaborator with the company rather than a headline addition.

Levitt’s public comments on the Board captured something essential about why computational approaches may be necessary rather than merely convenient for longevity drug discovery: “What excites me most about this Board is the combination of rigorous biological insight with the kind of large-scale computational power that can actually move the needle.” The hallmarks of aging involve dozens of interacting molecular processes across multiple cell types and tissues, operating across timescales from seconds to decades. No purely experimental approach can adequately model that complexity. Computational platforms that can simulate molecular interactions, predict off-target effects, and identify emergent behaviors across aging-related pathways are not supplements to biological reasoning. They are requirements for it.

That framing aligns with where the broader field of computational biology is moving. A 2024 review in Nature Aging examining AI applications in geroscience identified multi-modal foundation models, those trained simultaneously on genomics, proteomics, metabolomics, and clinical outcome data, as the most promising near-term frontier for identifying aging-relevant drug targets. Insilico’s PandaOmics platform is being developed along precisely these lines.

How This Fits the Broader AI Drug Discovery Wave

The Longevity Board announcement arrives at a moment when the AI drug discovery industry has crossed a decisive threshold. According to industry analysis published in April 2026, more than 173 AI-discovered drug programs are now in active clinical development globally, compared with essentially zero a decade ago. The pace is accelerating: Novo Nordisk’s partnership with OpenAI, NVIDIA’s $1 billion commitment to life sciences AI infrastructure, and a growing number of traditional pharmaceutical companies building in-house AI discovery capabilities all point toward a structural shift in how drugs are developed.

What makes Insilico’s Longevity Board distinctive in this landscape is the specificity of its focus. Most AI drug discovery companies are using their platforms to accelerate conventional drug development, finding better candidates faster against targets that have already been validated by traditional biology. Insilico is using its platform to attack a target class that has not yet been validated at the clinical level: the causal biology of human aging. The Longevity Board is the governance structure that will decide whether and how clinical validation attempts are designed.

This is not a small bet. If the Board’s clinical development programs generate compelling data in aging biomarkers alongside disease-specific endpoints, it will represent the first systematic pharmaceutical evidence that the hallmarks of aging are druggable in humans. That finding would reshape not just Insilico’s trajectory but the entire research agenda of the longevity medicine field.

The Competitive and Scientific Landscape

Insilico is not operating in isolation. Several other organizations are pursuing related ambitions. Unity Biotechnology has run clinical trials targeting senescent cells in ophthalmology and musculoskeletal disease, with mixed results that underscored the difficulty of translating senolytic biology into clinical efficacy. Calico Life Sciences, backed by Alphabet, has maintained a long-horizon research program focused on aging biology but has been deliberately opaque about its drug development timelines. Altos Labs and its large cohort of distinguished scientists has focused on cellular reprogramming as a route to biological rejuvenation.

What distinguishes Insilico’s approach is the combination of a proven generative AI platform, demonstrated Phase 2 clinical data in an aging-related indication, and now an institutional governance structure with the credibility and industry connections to drive clinical programs from early validation to potential approval. The Longevity Board is, in a sense, the organizational infrastructure that makes the clinical ambition credible.

The broader geroscience community has watched these developments with cautious interest. A perspective published in Aging Cell in 2025 argued that the field was approaching an inflection point at which the accumulation of positive preclinical data in multiple hallmark pathways, alongside improving biomarker panels for measuring biological age, would create the conditions for transformative clinical programs. The authors identified the absence of institutional infrastructure, including governance, funding, and regulatory strategy, as the primary bottleneck. The Longevity Board is a direct response to that bottleneck.

What This Means For You

The practical implications of Insilico’s Longevity Board will not be felt in clinics tomorrow. Clinical translation in the longevity space operates on timelines measured in years, not months. But the formation of this Board marks a meaningful milestone in the trajectory of longevity medicine, and understanding that trajectory is relevant to decisions people can make today.

First, the move reinforces what the best evidence in geroscience has been pointing toward for more than a decade: that aging itself is not an immutable fate but a biological process that can, in principle, be modified. The practical implication for healthspan today is to invest in the foundational behaviors that protect the same molecular systems the hallmarks framework describes: managing chronic inflammation through diet and movement, protecting mitochondrial function through aerobic training and sleep, supporting cellular proteostasis through nutrition that avoids chronic metabolic overload, and reducing genomic and epigenetic damage through avoiding known accelerators like smoking, excess alcohol, and unmanaged psychological stress.

Second, the dual-purpose target strategy Insilico is pursuing suggests that the next generation of drugs entering clinical trials for conditions like pulmonary fibrosis, neurodegenerative disease, and metabolic dysfunction may carry benefits for underlying aging biology that are measured and tracked as secondary endpoints. Paying attention to trial designs in this space over the next three to five years will be important for understanding what is actually coming down the pharmaceutical pipeline.

Third, and perhaps most importantly, the institutional weight now assembled around AI-driven longevity drug discovery, including a Nobel laureate, a major pharmaceutical executive, and demonstrated Phase 2 clinical data, signals that this field has crossed from aspirational to operational. The bridge between foundational wellness practices and pharmaceutical intervention in aging biology is being built from both ends. The question is no longer whether drugs targeting the hallmarks of aging will exist. The question is how long it will take, and whether we will be healthy enough to benefit when they arrive.

That is exactly the bridge Healthcare Discovery is built to help you navigate.

Sources: Insilico Medicine press release, April 21, 2026; Nature Medicine, rentosertib Phase 2a trial, 2025; Lopez-Otin et al., “The Hallmarks of Aging,” Cell, 2013 and 2023 update; GeroScience, senomorphic strategies review, 2025; Aging Cell, institutional bottlenecks in longevity medicine, 2025; Nature Aging, AI applications in geroscience, 2024.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.